NASDAQ:NXL • US65345B2016
The current stock price of NXL is 0.4229 USD. Today NXL is down by -2.29%. In the past month the price decreased by -16.27%. In the past year, price decreased by -79.87%.
ChartMill assigns a technical rating of 0 / 10 to NXL. When comparing the yearly performance of all stocks, NXL is a bad performer in the overall market: 97.58% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NXL. No worries on liquidiy or solvency for NXL as it has an excellent financial health rating, but there are worries on the profitability.
On November 14, 2025 NXL reported an EPS of -0.13 and a revenue of 18.15K. The company missed EPS expectations (-7.26% surprise) and missed revenue expectations (-55.07% surprise).
5 analysts have analysed NXL and the average price target is 4.08 USD. This implies a price increase of 864.77% is expected in the next year compared to the current price of 0.4229.
For the next year, analysts expect an EPS growth of 19.67% and a revenue growth 34.3% for NXL
Over the last trailing twelve months NXL reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 0.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.17 | 192.101B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.05 | 172.54B | ||
| SYK | STRYKER CORP | 22.93 | 137.252B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.79 | 103.813B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.52 | 49.778B | ||
| IDXX | IDEXX LABORATORIES INC | 40.62 | 47.68B | ||
| BDX | BECTON DICKINSON AND CO | 12 | 46.663B | ||
| RMD | RESMED INC | 19.63 | 35.999B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.07 | 33.147B | ||
| DXCM | DEXCOM INC | 26.14 | 26.09B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.99 | 17.941B | ||
| HOLX | HOLOGIC INC | 15.36 | 16.864B | ||
| PODD | INSULET CORP | 36.83 | 16.772B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
IPO: 2022-09-16
NEXALIN TECHNOLOGY INC
1776 Yorktown, Suite 550
Houston TEXAS US
Employees: 6
Phone: 18322600222
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
The current stock price of NXL is 0.4229 USD. The price decreased by -2.29% in the last trading session.
NXL does not pay a dividend.
NXL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NXL stock is listed on the Nasdaq exchange.
The Revenue of NEXALIN TECHNOLOGY INC (NXL) is expected to grow by 34.3% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
NEXALIN TECHNOLOGY INC (NXL) has a market capitalization of 7.89M USD. This makes NXL a Nano Cap stock.